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Correspondence Multislice Computed Tomography Angiography
for Noninvasive Assessment of the 18-Month
Performance of a Novel Radiolucent Bioresorbable
Vascular Scaffolding Device
The ABSORB Trial (A Clinical Evaluation of the Bioabsorbable
Everolimus Eluting Coronary Stent System in the Treatment of
Patients With de Novo Native Coronary Artery Lesions)To the Editor: Although metal stents revolutionized the treatment of
coronary artery disease, concerns exist about their indeﬁnite presence
and the risk of late stent thrombosis. This may be resolved by
biodegradable devices that provide initial support but dissolve over
time to restore native vessel integrity. Because the ﬁrst-generation
Absorb (Abbott Vascular, Santa Clara, California) everolimus-
eluting bioresorbable vascular scaffold (BVS) demonstrated late
lumen loss thought to be caused by rapid changes in strut integrity
(1), the second generation was designed for improved mechanical
endurance and prolonged radial force. The metal-free struts allow
unrestricted coronary computed tomography angiography (CCTA).
CCTA-based fractional ﬂow reserve (FFRCT) for functional coro-
nary artery disease assessment was recently introduced (2,3). In this
study, we evaluate the midterm clinical, angiographic, and functional
outcome of the second-generation Absorb BVS.
The ABSORB (A Clinical Evaluation of the Bioabsorbable
Everolimus Eluting Coronary Stent System in the Treatment of
Patients With de Novo Native Coronary Artery Lesions) trial
(NCT00856856) is a nonrandomized multicenter, single-arm, efﬁ-
cacy-safety study. At 12 centers, 101 patients (62.3  8.9 years of
age, 73 male) with 102 de novo lesions were treated with a second-
generation Absorb BVS (3). The balloon-expandable Absorb BVS
(diameter 3.0 mm, area 7.1 mm2) has a polylactide backbone con-
taining the antiproliferative drug everolimus. Elective procedures by
standard percutaneous coronary intervention techniques included
mandatory pre-dilation. The clinical composite endpoint at 18
months was cardiac death, myocardial infarction, or ischemia-driven
target lesion revascularization, as previously described (4).
Nine centers (79 patients) performed CCTA in 71 patients (90%)
with the use of 64-slice computed tomography technology or beyond
by standard techniques. Themedian radiation dose was 6.8 mSv (1.3
to 22.3 mSv). Vessel cross-sections were reconstructed at approxi-
mately 1-mm longitudinal increments, extending 5 mm beyond the
device, using the remaining platinum scaffold indicators as land-
marks (Circulation, Siemens AG, Forchheim, Germany). After
semiautomatic vessel lumen delineation, mean, minimal lumen area
(MLA), and maximum lumen areas were determined. The reference
lumen area was calculated as the average between themean vessel area
proximal and distal to the scaffolded segments. Area stenosis, deﬁned
as the difference between theMLA and the reference as a percentage
of the reference, 75% was considered signiﬁcant (Fig. 1).The FFRCT analysis was performed by HeartFlow, Inc.
(Redwood City, California). The methodology of FFRCT has been
described by Taylor et al. (3). On the basis of physiological mo-
deling, with input of clinical and CCTA data, coronary blood
ﬂow and pressure during hyperemia can be simulated. An
FFRCT <0.80, deﬁned as the ratio between coronary and aortic
computed mean pressure, was considered signiﬁcant. The FFRCT
gradient was calculated as the difference in FFRCT proximal and
distal to the scaffold site.
Continuous variables are presented as mean  SD or median
(range). The Pearson coefﬁcient was calculated to assess the
correlation among the MLA, area stenosis, and fractional ﬂow
reserve gradient (SPSS version 17.0, SPSS Inc., Chicago, Illinois).
No formal power calculation was performed.
At 18 months, there were no cardiac deaths and 3 non–Q-wave
myocardial infarctions: 2 during the index procedure, 1 during an
intercurrent invasive investigation, and 5 ischemia-driven target
lesion revascularizations. The hierarchical major adverse clinical
cardiac event rate was 7.9% (n ¼ 8).
Four CCTA scans (6%) were entirely noninterpretable, and
6 scans (8%) were only qualitatively evaluable. One of these
showed 50% stenosis, which was managed conservatively in the
absence of symptoms. Quantitatively (n ¼ 61), the average mean
in-scaffold lumen area was 5.1  1.4 mm2 (2.6 to 8.2 mm2), the
proximal and distal reference areas were 5.3  2.0 mm2 and 4.3 
1.5 mm2, respectively, the MLA was 3.5  1.0 mm2 (1.6 to 5.6
mm2), and the maximum lumen area was 7.0  2.1 mm2 (3.1 to
13.3 mm2). The average area stenosis was 22.7  22.4% (64.2%
to þ72.0%). The MLA was <25% of nominal in 1 case of a small
posterolateral branch (MLA 1.6 mm2, reference 2.1 mm2).
FFRCT could be performed in 38 patients (57%) and measured
0.92  0.06 (0.77 to 0.99) proximal and 0.89  0.06 (0.74 to 0.97)
distal to the scaffolded segment, with an average gradient of
0.03  0.04 (þ0.01 to 0.23). There was no signiﬁcant correlation
between area stenosis and MLA or FFRCT gradient. The largest
FFRCT gradient (0.23) was associated with only 9.4% area stenosis,
an MLA of 3.2 mm2, and low FFRCT values in all distal branches,
suggesting systematic underestimation. The FFRCT gradient ranged
between 0.02 and 0.09 in patients with an area stenosis 50%.
For decades, new percutaneous coronary therapies have required
invasive angiography to assess late lumen loss. Considering the good
Figure 1 CCTA and FFRCT Case Example
(A) On coronary computed tomography angiography (CCTA), remnant platinum markers (arrowheads) indicate the location of the previous scaffold placement in the left anterior
descending artery. Noncalciﬁed plaque results in 62% area stenosis. (B) Fractional ﬂow reserve (FFRCT) which is calculated throughout the coronary arteries and displayed as
yellow to red for low FFRCT and from blue to green within the normal range. (C) From the proximal to the distal edge of the scaffold, the FFRCT decreases from 0.88 to 0.80.
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1814diagnostic accuracy of CCTA in the absence of metal stents (5) and
the advantages in safety, patient convenience, and cost, CCTA offers
a noninvasive alternative to catheterization for both clinical care and
research. In this population, signiﬁcant re-stenosis after Absorb BVS
treatment was detected by CCTA in only 1 patient.
Study limitations are the nonrandomized design, cardiac CT
unavailability at 3 sites, and frequent noninterpretable FFRCT
analyses. The observation of absent hemodynamic signiﬁcance by
FFRCT in patients with mild stenosis should be interpreted as
explorative while the technique is further investigated.
The clinical event rate was acceptable (7.9%), and angiographic
patency by CCTA was good 18 months after implantation of the
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